Cardiometabolic Disease Market is predicted to reach USD ~868.45 Billion at a CAGR of ~24.00% during the forecast period 2023-2032

Market Research Future (MRFR) has published  on the “Cardiometabolic Disease Market”

Global Cardiometabolic Disease Market Highlights

The global cardiometabolic disease market accounts for a CAGR of 24.00% during the forecast period and is estimated to reach USD 868.45 billion by 2032.

Cardiometabolic Disease is a collection of metabolic dysfunctions frequently accompanied by a number of diseases, including impaired glucose tolerance, insulin resistance, central adiposity, hypertension, and dyslipidemia. Individuals with cardiometabolic disease are twice as likely to die from coronary heart disease and three times as likely to die from a heart attack or stroke, respectively.

Due to several factors, Cardiometabolic Disease and its associated comorbidities are among the most prevalent diseases worldwide. As a result of increased awareness and greater availability and access to cardiometabolic disease treatment options, certain diseases are no longer fatal if they are treated effectively and appropriately. This is expected to further contribute to the market's growth. The increased R&D for novel treatment options and the availability of therapeutics in emerging markets at subsidized prices are also anticipated to impact market growth positively.

Key Players

MRFR recognizes the following companies as the key players in the global cardiometabolic disease market— Cardax, Inc., Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Bayer AG, Allergan, Boehringer Ingelheim International GmbH, AstraZeneca and other players.

Segment Analysis

The global cardiometabolic disease market has been segmented based on treatment and distribution channel.

Based on treatment, the market is segmented into angiotensin-converting enzyme (ACE) inhibitors, diuretics, glucophage, and others. The angiotensin-converting enzyme (ACE) inhibitors segment was attributed to holding the largest market share in 2022.

The global cardiometabolic disease market has been segmented based on distribution channels into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment was expected to hold the largest market share in 2022.

Regional Analysis

The global cardiometabolic disease market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe cardiometabolic disease market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The cardiometabolic disease market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World’s cardiometabolic disease market comprises of Middle East, Africa, and Latin America.

The cardiometabolic disease market in North America will dominate this market. This region's ascent is responsible for increasing demand for healthcare products and expanding economies. The expanding knowledge about cardiometabolic disease among European consumers and the growing popularity of the healthcare industry are also significant market growth drivers.

Europe holds the second-largest market share for cardiometabolic diseases in 2022. This region has rising R&D expenditures, high healthcare costs, and an established healthcare industry.

From 2023 to 2032, the Asia-Pacific cardiometabolic disease market is anticipated to grow at the highest CAGR. Due to the region's swiftly expanding medical infrastructures, stringent government regulations on public healthcare, and major manufacturers' adoption of various market expansion strategies, Asia Pacific held a substantial market share during the forecast period.

Increasing public healthcare awareness and government initiatives in the Middle East & Africa, and Latin America will drive market growth.

Key Findings of the Study

• The global cardiometabolic disease market is expected to reach USD 868.45 billion by 2032, at a CAGR of 24.00% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market in 2022. The market in this region will be bolstered by the growing prevalence of various diseases and the increasing demand for various treatments.


• Based on distribution channels, the hospital pharmacies segment was attributed to holding the largest market in 2022, with an approximate market share of 35–45%.


• Cardax, Inc., Novartis AG, Novo Nordisk A/S, Eli Lilly and Company, Bayer AG, Allergan, Boehringer Ingelheim International GmbH, AstraZeneca, and other players are some of the key players.